<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351556</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH112432-01A1</org_study_id>
    <secondary_id>R01MH112432-01A1</secondary_id>
    <nct_id>NCT03351556</nct_id>
  </id_info>
  <brief_title>Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy</brief_title>
  <official_title>Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Berkeley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rasello</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health for a Prosperous Nation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Management and Development for Health in Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Berkeley</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Determine the &quot;dose-response&quot; relationship between a cash transfer amount and HIV viral
           suppression at 6 months

        2. Identify the most effective cash transfer size to increase the proportion of people
           living with HIV infection (PLHIV) retained in care and with suppressed viral load (&lt;1000
           copies/ml) after 6 months. (This amount will be further evaluated in a cluster
           randomized trial in Phase 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in the control group will receive the standard HIV primary care services
      according to Tanzania's National Guidelines for the Management of HIV and AIDS.

      The study has two active intervention arms:

        1. The opportunity to earn 10,000 TZS/month (~$4.50) for up to 6 months conditional on
           visit attendance, and

        2. The opportunity to earn 22,500 TZS/month (~$10.00) for up to 6 months conditional on
           visit attendance

      In both intervention arms, cash transfers will be delivered a maximum of once monthly, spaced
      ≥28 days apart, for up to six months and delivered via an automatic mobile money system
      linked to a biometric identification system.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Data collection and recruitment has been suspended due to the COVID-19 pandemic
  </why_stopped>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants in the cash transfer arms will be masked to the knowledge that there are two cash value arms.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>HIV viral suppression at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>&lt;1000 copies/ml</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">519</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Adherence, Medication</condition>
  <condition>Adherence, Patient</condition>
  <arm_group>
    <arm_group_label>Comparison Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in the comparison group will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Intervention 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month (~$4.50) for up to 6 months conditional on visit attendance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Intervention 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month (~$10.00) for up to 6 months conditional on visit attendance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Active Arm 1</intervention_name>
    <description>Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.</description>
    <arm_group_label>Active Intervention 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Active Arm 2</intervention_name>
    <description>Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.</description>
    <arm_group_label>Active Intervention 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years

          -  Living with HIV infection

          -  Initiated antiretroviral therapy ≤1 month prior to enrollment in the study

        Exclusion Criteria:

        - Participants who do no provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra I McCoy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Berkeley</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prosper Njau, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health for a Prosperous Nation and Ministry of Health, Community Development, Gender, Elderly, and Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kahama Hospital</name>
      <address>
        <city>Kahama</city>
        <state>Shinyanga Region</state>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagongwa Health Center</name>
      <address>
        <city>Shinyanga</city>
        <state>Shinyanga Region</state>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kambarage Health Center</name>
      <address>
        <city>Shinyanga</city>
        <state>Shinyanga Region</state>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinyanga Regional Referral Hospital</name>
      <address>
        <city>Shinyanga</city>
        <state>Shinyanga Region</state>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 19, 2017</study_first_submitted>
  <study_first_submitted_qc>November 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Berkeley</investigator_affiliation>
    <investigator_full_name>Sandra McCoy</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

